| 一般的な頻出語を「文章内」のリストから除外しています |
| 2語前 |
1語前 |
|
1語後 |
2語後 |
|
文章内 |
| and |
41 |
it |
48 |
|
unclear |
128 |
understood |
73 |
|
however |
236 |
| of |
36 |
has |
37 |
|
unknown |
90 |
be |
30 |
|
unclear |
135 |
| these |
24 |
the |
25 |
|
poorly |
75 |
in |
29 |
|
unknown |
109 |
| the |
22 |
have |
20 |
|
a |
70 |
to |
26 |
|
mechanisms |
94 |
| however |
20 |
and |
17 |
|
elusive |
64 |
and |
24 |
|
understood |
82 |
| this |
19 |
mechanisms |
14 |
|
largely |
38 |
for |
16 |
|
poorly |
81 |
| in |
18 |
that |
10 |
|
to |
32 |
whether |
15 |
|
elusive |
66 |
| molecular |
10 |
function |
9 |
|
the |
18 |
unknown |
15 |
|
cell |
64 |
| cell |
10 |
however |
8 |
|
challenging |
17 |
the |
14 |
|
although |
59 |
| underlying |
9 |
but |
8 |
|
limited |
16 |
unexplored |
14 |
|
patients |
58 |
| its |
7 |
to |
7 |
|
incompletely |
16 |
how |
14 |
|
despite |
58 |
| to |
7 |
cells |
7 |
|
stable |
16 |
challenge |
13 |
|
molecular |
56 |
| disease |
6 |
disease |
7 |
|
uncertain |
15 |
major |
11 |
|
disease |
51 |
| cancer |
6 |
infection |
7 |
|
in |
14 |
significant |
11 |
|
underlying |
49 |
| but |
6 |
who |
6 |
|
an |
13 |
characterized |
8 |
|
during |
46 |
| s |
5 |
there |
6 |
|
obscure |
10 |
due |
8 |
|
p |
45 |
| on |
5 |
cancer |
6 |
|
on |
10 |
but |
8 |
|
role |
44 |
| such |
5 |
this |
6 |
|
significant |
8 |
of |
8 |
|
cells |
44 |
| for |
5 |
patients |
6 |
|
high |
8 |
which |
7 |
|
largely |
43 |
| therapeutic |
4 |
mechanism |
6 |
|
unchanged |
8 |
because |
7 |
|
associated |
41 |
| patient |
4 |
population |
5 |
|
relatively |
8 |
with |
7 |
|
yet |
41 |
| a |
4 |
which |
5 |
|
unexplored |
7 |
defined |
7 |
|
function |
40 |
| cellular |
4 |
properties |
5 |
|
enigmatic |
6 |
as |
6 |
|
significant |
38 |
| that |
4 |
questions |
5 |
|
difficult |
6 |
challenging |
6 |
|
mechanism |
37 |
| with |
4 |
still |
4 |
|
undefined |
6 |
at |
5 |
|
challenge |
36 |
| heart |
4 |
association |
4 |
|
intact |
6 |
after |
5 |
|
cancer |
36 |
| clinical |
4 |
response |
4 |
|
constant |
5 |
even |
4 |
|
risk |
35 |
| cells |
3 |
effects |
3 |
|
debated |
5 |
critical |
4 |
|
development |
35 |
| species |
3 |
therapy |
3 |
|
significantly |
5 |
despite |
4 |
|
high |
34 |
| significant |
3 |
tissues |
3 |
|
controversial |
5 |
were |
4 |
|
treatment |
34 |
| by |
3 |
rates |
3 |
|
associated |
5 |
most |
4 |
|
many |
33 |
| human |
3 |
structures |
3 |
|
low |
5 |
on |
4 |
|
specific |
31 |
| pathways |
3 |
stroke |
3 |
|
poor |
4 |
during |
4 |
|
protein |
30 |
| within |
3 |
activation |
3 |
|
unresolved |
4 |
key |
4 |
|
clinical |
28 |
| their |
3 |
risk |
3 |
|
active |
4 |
unclear |
3 |
|
effects |
27 |
| t |
3 |
pathway |
3 |
|
one |
4 |
although |
3 |
|
low |
26 |
| brain |
3 |
therefore |
3 |
|
open |
4 |
untested |
3 |
|
brain |
25 |
| two |
3 |
sources |
3 |
|
elevated |
4 |
when |
3 |
|
one |
25 |
| after |
3 |
formation |
3 |
|
more |
4 |
by |
3 |
|
challenging |
25 |
| covid |
3 |
phenotype |
3 |
|
underexplored |
3 |
or |
3 |
|
s |
24 |
| bacterial |
3 |
state |
3 |
|
scarce |
3 |
low |
3 |
|
limited |
24 |
| related |
3 |
mutations |
3 |
|
after |
3 |
associated |
3 |
|
gene |
24 |
| asthma |
3 |
features |
3 |
|
understudied |
3 |
bottleneck |
2 |
|
major |
24 |
| those |
2 |
development |
3 |
|
localized |
3 |
suggesting |
2 |
|
years |
24 |
| rna |
2 |
proteins |
3 |
|
ambiguous |
3 |
elucidated |
2 |
|
due |
24 |
| expected |
2 |
functions |
3 |
|
sparse |
3 |
subject |
2 |
|
well |
24 |
| contemporary |
2 |
19 |
3 |
|
less |
3 |
unstudied |
2 |
|
functional |
23 |
| hepatic |
2 |
migration |
3 |
|
under |
3 |
uncharacterized |
2 |
|
control |
23 |
| female |
2 |
control |
3 |
|
similar |
3 |
improved |
2 |
|
processes |
23 |
| normal |
2 |
water |
3 |
|
bound |
2 |
their |
2 |
|
long |
23 |
| most |
2 |
challenges |
3 |
|
healthy |
2 |
elusive |
2 |
|
response |
23 |
| regulates |
2 |
dysfunction |
3 |
|
mysterious |
2 |
dialysis |
2 |
|
studies |
23 |
| scale |
2 |
resistance |
3 |
|
hospitalized |
2 |
until |
2 |
|
understanding |
22 |
| functional |
2 |
much |
3 |
|
as |
2 |
intact |
2 |
|
unexplored |
22 |
| sensory |
2 |
processes |
3 |
|
cases |
2 |
regarding |
2 |
|
human |
22 |
| dna |
2 |
interactions |
2 |
|
statistically |
2 |
constant |
2 |
|
known |
21 |
| immune |
2 |
assembly |
2 |
|
unexplained |
2 |
free |
2 |
|
structure |
21 |
| health |
2 |
learning |
2 |
|
however |
2 |
mystery |
2 |
|
stable |
21 |
| hospital |
2 |
structure |
2 |
|
asymptomatic |
2 |
owing |
2 |
|
genes |
20 |
| 01 |
2 |
surveillance |
2 |
|
only |
2 |
unmet |
2 |
|
study |
20 |
| free |
2 |
productivity |
2 |
|
hidden |
2 |
important |
2 |
|
only |
20 |
| endometrial |
2 |
responses |
2 |
|
tumor |
2 |
treatment |
2 |
|
large |
19 |
| genes |
2 |
effect |
2 |
|
incomplete |
2 |
especially |
2 |
|
expression |
19 |
| heterogeneous |
2 |
often |
2 |
|
independent |
2 |
under |
2 |
|
outcomes |
19 |
| cortical |
2 |
stability |
2 |
|
critical |
2 |
over |
2 |
|
factors |
19 |
| association |
2 |
reactivity |
2 |
|
unsolved |
2 |
risk |
2 |
|
analysis |
19 |
| motor |
2 |
vivo |
2 |
|
regarding |
2 |
about |
2 |
|
other |
19 |
| particular |
2 |
9 |
2 |
|
cytosolic |
2 |
common |
2 |
|
important |
19 |
| from |
2 |
injury |
2 |
|
reduced |
2 |
6 |
2 |
|
related |
18 |
| phenotypic |
2 |
species |
2 |
|
uncharacterized |
2 |
stable |
2 |
|
therapeutic |
18 |
| transport |
2 |
progression |
2 |
|
at |
2 |
between |
2 |
|
activation |
18 |
| right |
2 |
stress |
2 |
|
central |
2 |
than |
2 |
|
into |
18 |
| cardiac |
2 |
materials |
2 |
|
3 |
2 |
across |
2 |
|
cause |
18 |
| across |
2 |
coordination |
2 |
|
challenges |
2 |
outstanding |
1 |
|
proteins |
18 |
| as |
2 |
homeostasis |
2 |
|
remarkably |
1 |
limited |
1 |
|
increased |
18 |
| nevertheless |
2 |
mortality |
2 |
|
negative |
1 |
21 |
1 |
|
model |
18 |
| neural |
2 |
while |
2 |
|
unreliable |
1 |
it |
1 |
|
level |
18 |
| groups |
2 |
pigment |
2 |
|
underused |
1 |
regional |
1 |
|
all |
18 |
| between |
2 |
immunity |
2 |
|
sensitive |
1 |
fold |
1 |
|
immune |
18 |
| yet |
2 |
rnas |
2 |
|
suboptimal |
1 |
our |
1 |
|
range |
18 |
| 12 |
2 |
phenomena |
2 |
|
unidentified |
1 |
flcn |
1 |
|
activity |
17 |
| acquired |
2 |
growth |
2 |
|
alive |
1 |
synapses |
1 |
|
active |
17 |
| treatment |
2 |
sites |
2 |
|
100 |
1 |
standard |
1 |
|
among |
17 |
| whether |
2 |
variation |
2 |
|
genes |
1 |
its |
1 |
|
regulation |
17 |
| thus |
2 |
54 |
2 |
|
insufficiently |
1 |
primary |
1 |
|
results |
17 |
| metabolic |
2 |
communities |
2 |
|
ribbon |
1 |
particularly |
1 |
|
because |
17 |
| important |
2 |
those |
2 |
|
scarcely |
1 |
second |
1 |
|
use |
17 |
| tissue |
2 |
largely |
2 |
|
despite |
1 |
described |
1 |
|
signaling |
17 |
| virus |
2 |
nm |
2 |
|
computationally |
1 |
potent |
1 |
|
10 |
17 |
| causes |
2 |
physiology |
2 |
|
topics |
1 |
intense |
1 |
|
potential |
17 |
| cognitive |
2 |
results |
2 |
|
0 |
1 |
1 |
1 |
|
complex |
17 |
| analysis |
2 |
outcome |
2 |
|
prohibitive |
1 |
resolved |
1 |
|
acute |
17 |
| 2 |
2 |
process |
2 |
|
strong |
1 |
autocrine |
1 |
|
incompletely |
17 |
| gamma |
2 |
question |
2 |
|
extent |
1 |
oud |
1 |
|
across |
17 |
| methylation |
2 |
md |
2 |
|
nontoxic |
1 |
reviewed |
1 |
|
health |
17 |
| enteric |
2 |
tb |
2 |
|
first |
1 |
all |
1 |
|
infection |
17 |
| protein |
2 |
regions |
2 |
|
admitted |
1 |
formidable |
1 |
|
significantly |
17 |
| it |
2 |
release |
2 |
|
cytoplasmic |
1 |
costly |
1 |
|
data |
17 |
| drug |
2 |
use |
2 |
|
among |
1 |
5 |
1 |
|
growth |
16 |
| has |
2 |
will |
2 |
|
unaltered |
1 |
scientific |
1 |
|
dynamics |
16 |
| regulatory |
2 |
exposure |
2 |
|
numerous |
1 |
odds |
1 |
|
n |
16 |
| mechanical |
2 |
repair |
2 |
|
886 |
1 |
backward |
1 |
|
species |
16 |
| benefits |
2 |
morbidity |
2 |
|
151 |
1 |
line |
1 |
|
whereas |
16 |
| subsequent |
2 |
data |
2 |
|
opaque |
1 |
had |
1 |
|
nature |
16 |
| biological |
2 |
events |
2 |
|
compromised |
1 |
limiting |
1 |
|
recent |
16 |
| transcriptional |
2 |
obesity |
2 |
|
especially |
1 |
upon |
1 |
|
interactions |
15 |
| 0 |
2 |
they |
2 |
|
well |
1 |
globally |
1 |
|
95 |
15 |
| several |
2 |
repression |
2 |
|
29 |
1 |
public |
1 |
|
even |
15 |
| interferometry |
1 |
interaction |
2 |
|
long |
1 |
largely |
1 |
|
conditions |
15 |
| synaptic |
1 |
regulation |
2 |
|
recommendations |
1 |
126 |
1 |
|
tumor |
15 |
| rrt |
1 |
action |
2 |
|
atl |
1 |
patients |
1 |
|
dna |
15 |
| spindle |
1 |
enzymes |
2 |
|
109 |
1 |
mainly |
1 |
|
under |
15 |
| observational |
1 |
domestication |
2 |
|
4 |
1 |
unsolved |
1 |
|
uncertain |
15 |
| additional |
1 |
long |
2 |
|
gaps |
1 |
down |
1 |
|
structures |
15 |
| cable |
1 |
pairs |
2 |
|
unvalidated |
1 |
up |
1 |
|
mutations |
15 |
| hcc |
1 |
dynamics |
2 |
|
plastic |
1 |
treated |
1 |
|
cellular |
15 |
| grain |
1 |
knowledge |
2 |
|
lifespan |
1 |
plagued |
1 |
|
changes |
15 |
| resulting |
1 |
phenotypes |
2 |
|
little |
1 |
sex |
1 |
|
t |
15 |
| holoreceptors |
1 |
types |
2 |
|
475 |
1 |
tissues |
1 |
|
thus |
15 |
| is |
1 |
selection |
2 |
|
participants |
1 |
human |
1 |
|
both |
15 |
| inflammatory |
1 |
pattern |
2 |
|
prominent |
1 |
adjustment |
1 |
|
age |
15 |
| akt |
1 |
signaling |
2 |
|
highly |
1 |
term |
1 |
|
hiv |
15 |
| allergic |
1 |
context |
2 |
|
cost |
1 |
clinics |
1 |
|
common |
15 |
| which |
1 |
failure |
2 |
|
hours |
1 |
benign |
1 |
|
evidence |
15 |
| viral |
1 |
would |
2 |
|
deficient |
1 |
partly |
1 |
|
using |
14 |
| transplantation |
1 |
polarity |
2 |
|
attractive |
1 |
predictors |
1 |
|
pathways |
14 |
| capsular |
1 |
neurons |
2 |
|
unavailable |
1 |
possibly |
1 |
|
survival |
14 |
| mast |
1 |
outcomes |
2 |
|
two |
1 |
optimize |
1 |
|
rates |
14 |
| bystander |
1 |
capacity |
1 |
|
conceptual |
1 |
tg |
1 |
|
current |
14 |
| regimes |
1 |
bacteria |
1 |
|
conserved |
1 |
beyond |
1 |
|
single |
14 |
| hormone |
1 |
burns |
1 |
|
we |
1 |
attention |
1 |
|
observed |
14 |
| spb |
1 |
achieved |
1 |
|
unelucidated |
1 |
within |
1 |
|
genetic |
14 |
| junction |
1 |
embryos |
1 |
|
problematic |
1 |
asymptomatic |
1 |
|
mortality |
14 |
| larger |
1 |
consequences |
1 |
|
80 |
1 |
technical |
1 |
|
induced |
14 |
| restenosis |
1 |
inhibitors |
1 |
|
anchored |
1 |
pinnacle |
1 |
|
based |
14 |
| movement |
1 |
reactions |
1 |
|
graft |
1 |
through |
1 |
|
12 |
14 |
| tsdr |
1 |
extent |
1 |
|
unspecified |
1 |
oxidative |
1 |
|
higher |
13 |
| cause |
1 |
strains |
1 |
|
higher |
1 |
substantial |
1 |
|
ci |
13 |
| chemotherapy |
1 |
also |
1 |
|
latent |
1 |
puzzling |
1 |
|
non |
13 |
| genome |
1 |
ltx |
1 |
|
uninfected |
1 |
computational |
1 |
|
mediated |
13 |
| affective |
1 |
ad |
1 |
|
predominant |
1 |
effective |
1 |
|
two |
13 |
| guide |
1 |
access |
1 |
|
standing |
1 |
understudied |
1 |
|
tissue |
13 |
| whereas |
1 |
polysaccharide |
1 |
|
uncertainty |
1 |
development |
1 |
|
progression |
13 |
| pharmacology |
1 |
practice |
1 |
|
substantial |
1 |
case |
1 |
|
up |
13 |
| sleep |
1 |
fibrosis |
1 |
|
rate |
1 |
given |
1 |
|
characterized |
13 |
| whose |
1 |
mice |
1 |
|
equivocal |
1 |
if |
1 |
|
therapy |
13 |
| relapsed |
1 |
gaps |
1 |
|
indistinguishable |
1 |
acceptable |
1 |
|
through |
13 |
| cortex |
1 |
five |
1 |
|
stably |
1 |
grand |
1 |
|
methods |
13 |
| 55 |
1 |
scarb2 |
1 |
|
study |
1 |
utilized |
1 |
|
patterns |
13 |
| constraint |
1 |
areas |
1 |
|
mrd |
1 |
ever |
1 |
|
relationship |
13 |
| dependent |
1 |
chance |
1 |
|
mostly |
1 |
experimental |
1 |
|
similar |
13 |
| serca |
1 |
individual |
1 |
|
expensive |
1 |
focus |
1 |
|
identified |
13 |
| mendelian |
1 |
should |
1 |
|
acute |
1 |
propose |
1 |
|
001 |
13 |
| myocardial |
1 |
deficits |
1 |
|
six |
1 |
well |
1 |
|
factor |
13 |
| at |
1 |
interventions |
1 |
|
and |
1 |
excellent |
1 |
|
over |
13 |
| trigger |
1 |
vinculin |
1 |
|
clinically |
1 |
identify |
1 |
|
key |
13 |
| canonical |
1 |
patterns |
1 |
|
impaired |
1 |
foremost |
1 |
|
defined |
13 |
| lc |
1 |
nih |
1 |
|
such |
1 |
particles |
1 |
|
stability |
12 |
| immunosuppressive |
1 |
relationship |
1 |
|
uncultured |
1 |
therapeutic |
1 |
|
basis |
12 |
| neuroendocrine |
1 |
loci |
1 |
|
hitherto |
1 |
widely |
1 |
|
different |
12 |
| they |
1 |
sms |
1 |
|
drug |
1 |
hindering |
1 |
|
compared |
12 |
| atomistic |
1 |
etiologies |
1 |
|
close |
1 |
exon |
1 |
|
rna |
12 |
| effects |
1 |
numbers |
1 |
|
unaddressed |
1 |
where |
1 |
|
consequences |
12 |
| organ |
1 |
regimens |
1 |
|
safety |
1 |
appreciated |
1 |
|
lack |
12 |
| activation |
1 |
crucially |
1 |
|
remitted |
1 |
following |
1 |
|
process |
12 |
| oxides |
1 |
tumors |
1 |
|
able |
1 |
fruitful |
1 |
|
resistance |
12 |
| requirement |
1 |
arise |
1 |
|
discriminatory |
1 |
chromatin |
1 |
|
vivo |
12 |
| carbon |
1 |
simulations |
1 |
|
seated |
1 |
along |
1 |
|
particular |
12 |
| sensitivity |
1 |
all |
1 |
|
hindered |
1 |
tedious |
1 |
|
properties |
12 |
| tract |
1 |
distributions |
1 |
|
somewhat |
1 |
ratios |
1 |
|
leading |
12 |
| hybrid |
1 |
serotypes |
1 |
|
favored |
1 |
methodswe |
1 |
|
death |
12 |
| perinatal |
1 |
etc |
1 |
|
concentrated |
1 |
obstacle |
1 |
|
term |
12 |
| m |
1 |
ntds |
1 |
|
extremely |
1 |
elevated |
1 |
|
about |
12 |
| vacancy |
1 |
chondrogenesis |
1 |
|
very |
1 |
contentious |
1 |
|
biological |
12 |
| substrate |
1 |
eruptions |
1 |
|
unclarified |
1 |
independent |
1 |
|
cases |
12 |
| cord |
1 |
climate |
1 |
|
prognostic |
1 |
samples |
1 |
|
impact |
12 |
| clade |
1 |
imaging |
1 |
|
possible |
1 |
coordinate |
1 |
|
responsible |
12 |
| radiomic |
1 |
adaptation |
1 |
|
unable |
1 |
identifying |
1 |
|
found |
12 |
| fungal |
1 |
information |
1 |
|
muoo |
1 |
we |
1 |
|
virus |
12 |
| size |
1 |
metazoans |
1 |
|
cognitively |
1 |
why |
1 |
|
months |
12 |
| inhibitor |
1 |
binding |
1 |
|
crucial |
1 |
unresolved |
1 |
|
diseases |
12 |
| adjustment |
1 |
mt |
1 |
|
technically |
1 |
infectious |
1 |
|
drug |
12 |
| familial |
1 |
proteome |
1 |
|
present |
1 |
frequent |
1 |
|
water |
12 |
| global |
1 |
evolution |
1 |
|
lower |
1 |
intractable |
1 |
|
neurons |
12 |
| interaction |
1 |
suite |
1 |
|
of |
1 |
crucial |
1 |
|
life |
11 |
| aggregate |
1 |
drugs |
1 |
|
constituting |
1 |
strands |
1 |
|
population |
11 |
| golgi |
1 |
opoa |
1 |
|
flat |
1 |
barrier |
1 |
|
negative |
11 |
| degradation |
1 |
plants |
1 |
|
relevant |
1 |
open |
1 |
|
challenges |
11 |
| lactams |
1 |
lung |
1 |
|
unaffected |
1 |
lack |
1 |
|
primary |
11 |
| migraine |
1 |
mdscs |
1 |
|
variable |
1 |
altered |
1 |
|
functions |
11 |
| cases |
1 |
electrode |
1 |
|
nearly |
1 |
ms |
1 |
|
critical |
11 |
| ce |
1 |
problems |
1 |
|
ultrashort |
1 |
what |
1 |
|
global |
11 |
| infants |
1 |
conformations |
1 |
|
avoidance |
1 |
concerns |
1 |
|
individual |
11 |
| other |
1 |
radiation |
1 |
|
alpha2 |
1 |
topic |
1 |
|
formation |
11 |
| ck1alpha |
1 |
datasets |
1 |
|
effective |
1 |
high |
1 |
|
care |
11 |
| micro |
1 |
underpinnings |
1 |
|
stacked |
1 |
leading |
1 |
|
states |
11 |
| diseases |
1 |
metabolism |
1 |
|
airborne |
1 |
similar |
1 |
|
relatively |
11 |
| broader |
1 |
t2d |
1 |
|
invariant |
1 |
clear |
1 |
|
established |
11 |
| hydroclimate |
1 |
sensitivity |
1 |
|
uninvestigated |
1 |
quartiles |
1 |
|
features |
11 |
| sole |
1 |
wt |
1 |
|
for |
1 |
interest |
1 |
|
plant |
11 |
| host |
1 |
total |
1 |
|
faithful |
1 |
unchanged |
1 |
|
carbon |
11 |
| oocyte |
1 |
ppi |
1 |
|
independently |
1 |
though |
1 |
|
state |
11 |
| ill |
1 |
chrcc |
1 |
|
dynamic |
1 |
region |
1 |
|
analyses |
11 |
| binding |
1 |
covariates |
1 |
|
distinct |
1 |
matter |
1 |
|
no |
11 |
| early |
1 |
impacts |
1 |
|
qualitatively |
1 |
t2 |
1 |
|
neural |
11 |
| process |
1 |
calculus |
1 |
|
narrow |
1 |
unfulfilled |
1 |
|
ratio |
11 |
| regulate |
1 |
cytoplasm |
1 |
|
virtually |
1 |
care |
1 |
|
free |
11 |
| dynamic |
1 |
apparatus |
1 |
|
whether |
1 |
mainstay |
1 |
|
sites |
11 |
| analyses |
1 |
survival |
1 |
|
common |
1 |
viable |
1 |
|
ms |
11 |
| spxa2 |
1 |
lot |
1 |
|
ill |
1 |
disconnected |
1 |
|
events |
11 |
| phenotypical |
1 |
26 |
1 |
|
2228 |
1 |
several |
1 |
|
systems |
11 |
| noncanonical |
1 |
possibility |
1 |
|
untested |
1 |
central |
1 |
|
if |
11 |
| range |
1 |
yap |
1 |
|
widely |
1 |
analyzed |
1 |
|
metabolic |
11 |
| hiv |
1 |
sepsis |
1 |
|
wild |
1 |
trials |
1 |
|
information |
10 |
| ecosystem |
1 |
hand |
1 |
|
focused |
1 |
valid |
1 |
|
though |
10 |
| 5 |
1 |
mutation |
1 |
|
rare |
1 |
indicating |
1 |
|
regulatory |
10 |
| dream |
1 |
environments |
1 |
|
exactly |
1 |
small |
1 |
|
methylation |
10 |
| denv |
1 |
variability |
1 |
|
it |
1 |
step |
1 |
|
responses |
10 |
| kpa |
1 |
hierarchy |
1 |
|
when |
1 |
response |
1 |
|
importance |
10 |
| diverse |
1 |
gbeta |
1 |
|
flexible |
1 |
women |
1 |
|
strategy |
10 |
| severe |
1 |
pathomechanisms |
1 |
|
undetectable |
1 |
quiescent |
1 |
|
precise |
10 |
| extinction |
1 |
always |
1 |
|
22 |
1 |
used |
1 |
|
patient |
10 |
| neuronal |
1 |
neurodevelopment |
1 |
|
sns |
1 |
type |
1 |
|
versus |
10 |
| us |
1 |
photoactivation |
1 |
|
far |
1 |
replicated |
1 |
|
relevance |
10 |
| prevalent |
1 |
pcp |
1 |
|
about |
1 |
gold |
1 |
|
levels |
10 |
| 22 |
1 |
particular |
1 |
|
|
|
mtx |
1 |
|
lower |
10 |
| likely |
1 |
incidence |
1 |
|
|
|
suppression |
1 |
|
roles |
10 |
| biophysical |
1 |
longevity |
1 |
|
|
|
variables |
1 |
|
unchanged |
10 |
| cigarette |
1 |
traits |
1 |
|
|
|
image |
1 |
|
rate |
10 |
| assisted |
1 |
roles |
1 |
|
|
|
using |
1 |
|
ability |
10 |
| relevance |
1 |
phages |
1 |
|
|
|
guiding |
1 |
|
loss |
10 |
| direction |
1 |
uniformity |
1 |
|
|
|
items |
1 |
|
infected |
10 |
| 100 |
1 |
strength |
1 |
|
|
|
below |
1 |
|
research |
10 |
| when |
1 |
neuropathogenesis |
1 |
|
|
|
local |
1 |
|
number |
10 |
| cleavage |
1 |
blood |
1 |
|
|
|
investigation |
1 |
|
mechanistic |
10 |
| further |
1 |
transitions |
1 |
|
|
|
|
|
|
pathway |
10 |
| cprnfl |
1 |
suvs |
1 |
|
|
|
|
|
|
knowledge |
10 |
| attributable |
1 |
interface |
1 |
|
|
|
|
|
|
obscure |
10 |
| ag |
1 |
actuation |
1 |
|
|
|
|
|
|
therefore |
10 |
| depot |
1 |
contents |
1 |
|
|
|
|
|
|
stress |
10 |
| graft |
1 |
immunopathogenesis |
1 |
|
|
|
|
|
|
like |
10 |
| oxide |
1 |
ecosystems |
1 |
|
|
|
|
|
|
light |
10 |
| endorse |
1 |
drought |
1 |
|
|
|
|
|
|
sensitivity |
10 |
| retained |
1 |
condors |
1 |
|
|
|
|
|
|
climate |
10 |
| intervention |
1 |
crosstalk |
1 |
|
|
|
|
|
|
some |
10 |
| pore |
1 |
tumorigenesis |
1 |
|
|
|
|
|
|
association |
10 |
| microbial |
1 |
lpm |
1 |
|
|
|
|
|
|
signal |
10 |
| carriers |
1 |
groupings |
1 |
|
|
|
|
|
|
regarding |
10 |
| coordinated |
1 |
smoking |
1 |
|
|
|
|
|
|
heart |
10 |
| oscillation |
1 |
threading |
1 |
|
|
|
|
|
|
system |
10 |
| systems |
1 |
skeleton |
1 |
|
|
|
|
|
|
sample |
10 |
| conformational |
1 |
tuning |
1 |
|
|
|
|
|
|
women |
10 |
| coastal |
1 |
paee |
1 |
|
|
|
|
|
|
lipid |
9 |
| redox |
1 |
prognosis |
1 |
|
|
|
|
|
|
affect |
9 |
| dehydrogenase |
1 |
event |
1 |
|
|
|
|
|
|
difficult |
9 |
| prostate |
1 |
thickness |
1 |
|
|
|
|
|
|
assembly |
9 |
| nash |
1 |
ablate |
1 |
|
|
|
|
|
|
effect |
9 |
| usage |
1 |
38 |
1 |
|
|
|
|
|
|
source |
9 |
| dr |
1 |
differences |
1 |
|
|
|
|
|
|
additional |
9 |
| assembly |
1 |
encounter |
1 |
|
|
|
|
|
|
baseline |
9 |
| proteins |
1 |
separation |
1 |
|
|
|
|
|
|
energy |
9 |
| lymphoid |
1 |
rejection |
1 |
|
|
|
|
|
|
particularly |
9 |
| spatiotemporally |
1 |
photoanodes |
1 |
|
|
|
|
|
|
surface |
9 |
| millet |
1 |
antarctica |
1 |
|
|
|
|
|
|
few |
9 |
| 2oa |
1 |
whales |
1 |
|
|
|
|
|
|
19 |
9 |
| much |
1 |
transcripts |
1 |
|
|
|
|
|
|
lung |
9 |
| pursue |
1 |
pathophysiology |
1 |
|
|
|
|
|
|
studied |
9 |
| reducing |
1 |
frequency |
1 |
|
|
|
|
|
|
including |
9 |
| body |
1 |
va |
1 |
|
|
|
|
|
|
activities |
9 |
| fluorescent |
1 |
approach |
1 |
|
|
|
|
|
|
follow |
9 |
| individuals |
1 |
ensemble |
1 |
|
|
|
|
|
|
binding |
9 |
| severity |
1 |
chemistry |
1 |
|
|
|
|
|
|
tissues |
9 |
| processes |
1 |
nature |
1 |
|
|
|
|
|
|
improved |
9 |
| states |
1 |
tme |
1 |
|
|
|
|
|
|
revealed |
9 |
| numerous |
1 |
oadh |
1 |
|
|
|
|
|
|
against |
9 |
| neuroanatomical |
1 |
determinants |
1 |
|
|
|
|
|
|
showed |
9 |
| expectation |
1 |
hpv16 |
1 |
|
|
|
|
|
|
poor |
9 |
| lipid |
1 |
biomarkers |
1 |
|
|
|
|
|
|
causes |
9 |
| myotube |
1 |
biases |
1 |
|
|
|
|
|
|
constant |
9 |
| asynchronous |
1 |
diverticulosis |
1 |
|
|
|
|
|
|
transcriptional |
9 |
| trained |
1 |
sequences |
1 |
|
|
|
|
|
|
c |
9 |
| pathway |
1 |
malignancies |
1 |
|
|
|
|
|
|
recognition |
9 |
| cpr |
1 |
coordinated |
1 |
|
|
|
|
|
|
change |
9 |
| energy |
1 |
epilepsy |
1 |
|
|
|
|
|
|
several |
9 |
| all |
1 |
mmud |
1 |
|
|
|
|
|
|
central |
9 |
| regulating |
1 |
genotypes |
1 |
|
|
|
|
|
|
individuals |
9 |
| significantly |
1 |
intermediate |
1 |
|
|
|
|
|
|
diversity |
9 |
| activated |
1 |
work |
1 |
|
|
|
|
|
|
failure |
9 |
| acyclic |
1 |
lvad |
1 |
|
|
|
|
|
|
coronavirus |
9 |
| polymer |
1 |
atmosphere |
1 |
|
|
|
|
|
|
interaction |
9 |
| brincidofovir |
1 |
size |
1 |
|
|
|
|
|
|
per |
9 |
| antigenic |
1 |
diagnosis |
1 |
|
|
|
|
|
|
provide |
9 |
| complexoform |
1 |
details |
1 |
|
|
|
|
|
|
detection |
9 |
| ii |
1 |
activity |
1 |
|
|
|
|
|
|
muscle |
9 |
| nature |
1 |
increased |
1 |
|
|
|
|
|
|
multiple |
9 |
| eukaryotic |
1 |
involved |
1 |
|
|
|
|
|
|
group |
9 |
| system |
1 |
reactivations |
1 |
|
|
|
|
|
|
differences |
9 |
| application |
1 |
exist |
1 |
|
|
|
|
|
|
reduced |
9 |
| trans |
1 |
correlates |
1 |
|
|
|
|
|
|
findings |
9 |
| animal |
1 |
signals |
1 |
|
|
|
|
|
|
natural |
8 |
| savings |
1 |
accumulation |
1 |
|
|
|
|
|
|
overall |
8 |
| lytic |
1 |
guidance |
1 |
|
|
|
|
|
|
learning |
8 |
| surface |
1 |
phoms |
1 |
|
|
|
|
|
|
transfer |
8 |
| bp |
1 |
on |
1 |
|
|
|
|
|
|
evolutionary |
8 |
| tubulin |
1 |
duration |
1 |
|
|
|
|
|
|
involved |
8 |
| herbivore |
1 |
centres |
1 |
|
|
|
|
|
|
various |
8 |
| nlr |
1 |
connections |
1 |
|
|
|
|
|
|
further |
8 |
| intake |
1 |
anxiety |
1 |
|
|
|
|
|
|
viral |
8 |
| designable |
1 |
hf |
1 |
|
|
|
|
|
|
covid |
8 |
| inland |
1 |
virus |
1 |
|
|
|
|
|
|
inhibition |
8 |
| therefore |
1 |
absence |
1 |
|
|
|
|
|
|
year |
8 |
| ipf |
1 |
hyperproliferative |
1 |
|
|
|
|
|
|
dynamic |
8 |
| understanding |
1 |
olefins |
1 |
|
|
|
|
|
|
novel |
8 |
| variants |
1 |
strands |
1 |
|
|
|
|
|
|
relative |
8 |
| working |
1 |
scalp |
1 |
|
|
|
|
|
|
degree |
8 |
| outside |
1 |
epitopes |
1 |
|
|
|
|
|
|
populations |
8 |
| myelin |
1 |
pausing |
1 |
|
|
|
|
|
|
being |
8 |
| atomic |
1 |
pathogenesis |
1 |
|
|
|
|
|
|
used |
8 |
| terl |
1 |
23 |
1 |
|
|
|
|
|
|
cognitive |
8 |
| 79 |
1 |
ni |
1 |
|
|
|
|
|
|
participants |
8 |
| 1 |
1 |
transcriptomes |
1 |
|
|
|
|
|
|
effective |
8 |
| hcmv |
1 |
pneumonia |
1 |
|
|
|
|
|
|
target |
8 |
| passive |
1 |
macroscale |
1 |
|
|
|
|
|
|
invasive |
8 |
| notwithstanding |
1 |
smce |
1 |
|
|
|
|
|
|
whose |
8 |
| bacteria |
1 |
violaxanthin |
1 |
|
|
|
|
|
|
origin |
8 |
| technical |
1 |
reactivation |
1 |
|
|
|
|
|
|
i |
8 |
| infrared |
1 |
detyrosination |
1 |
|
|
|
|
|
|
physiological |
8 |
| ssmlm |
1 |
recognition |
1 |
|
|
|
|
|
|
eye |
8 |
| proportions |
1 |
amounts |
1 |
|
|
|
|
|
|
absence |
8 |
| transplant |
1 |
fisheries |
1 |
|
|
|
|
|
|
without |
8 |
| representative |
1 |
clearance |
1 |
|
|
|
|
|
|
variation |
8 |
| positive |
1 |
diversity |
1 |
|
|
|
|
|
|
especially |
8 |
| receptors |
1 |
memory |
1 |
|
|
|
|
|
|
chromatin |
8 |
| ma |
1 |
systems |
1 |
|
|
|
|
|
|
approach |
8 |
| vertebrates |
1 |
asia |
1 |
|
|
|
|
|
|
physical |
8 |
| specific |
1 |
resolution |
1 |
|
|
|
|
|
|
gamma |
8 |
| adverse |
1 |
protein |
1 |
|
|
|
|
|
|
severe |
8 |
| differences |
1 |
eye |
1 |
|
|
|
|
|
|
complexity |
8 |
| spatially |
1 |
planta |
1 |
|
|
|
|
|
|
controlling |
8 |
| fiber |
1 |
networks |
1 |
|
|
|
|
|
|
onset |
8 |
| metal |
1 |
stretch |
1 |
|
|
|
|
|
|
present |
8 |
| although |
1 |
strategies |
1 |
|
|
|
|
|
|
recovery |
8 |
| conventional |
1 |
lymphoma |
1 |
|
|
|
|
|
|
questions |
8 |
| stoichiometries |
1 |
treatment |
1 |
|
|
|
|
|
|
breast |
8 |
| fire |
1 |
limitations |
1 |
|
|
|
|
|
|
intact |
8 |
| mrna |
1 |
screening |
1 |
|
|
|
|
|
|
time |
8 |
| 59 |
1 |
what |
1 |
|
|
|
|
|
|
models |
8 |
| antiicing |
1 |
7 |
1 |
|
|
|
|
|
|
exercise |
8 |
| institutional |
1 |
ostomies |
1 |
|
|
|
|
|
|
behavior |
8 |
| percentage |
1 |
affect |
1 |
|
|
|
|
|
|
efficient |
7 |
| term |
1 |
prrs |
1 |
|
|
|
|
|
|
improve |
7 |
| tumor |
1 |
essentially |
1 |
|
|
|
|
|
|
metabolism |
7 |
| dhea |
1 |
actions |
1 |
|
|
|
|
|
|
resulting |
7 |
| 202 |
1 |
uncertainty |
1 |
|
|
|
|
|
|
management |
7 |
| observed |
1 |
source |
1 |
|
|
|
|
|
|
still |
7 |
| disorder |
1 |
goal |
1 |
|
|
|
|
|
|
extent |
7 |
| enzymes |
1 |
chemotherapies |
1 |
|
|
|
|
|
|
impacts |
7 |
| 1a |
1 |
chaperones |
1 |
|
|
|
|
|
|
elucidated |
7 |
| offs |
1 |
rate |
1 |
|
|
|
|
|
|
mice |
7 |
| individual |
1 |
concert |
1 |
|
|
|
|
|
|
healthy |
7 |
| live |
1 |
regime |
1 |
|
|
|
|
|
|
normal |
7 |
| ime1 |
1 |
translation |
1 |
|
|
|
|
|
|
determined |
7 |
| infarction |
1 |
proliferation |
1 |
|
|
|
|
|
|
release |
7 |
| european |
1 |
2 |
1 |
|
|
|
|
|
|
likely |
7 |
| inflammasome |
1 |
challenge |
1 |
|
|
|
|
|
|
presence |
7 |
| stroke |
1 |
susceptibility |
1 |
|
|
|
|
|
|
previously |
7 |
| replisomes |
1 |
surfaces |
1 |
|
|
|
|
|
|
types |
7 |
| blood |
1 |
constraints |
1 |
|
|
|
|
|
|
spatial |
7 |
| taste |
1 |
of |
1 |
|
|
|
|
|
|
region |
7 |
| glun2a |
1 |
health |
1 |
|
|
|
|
|
|
genome |
7 |
| n |
1 |
microenvironment |
1 |
|
|
|
|
|
|
structural |
7 |
| chip |
1 |
pc |
1 |
|
|
|
|
|
|
surgical |
7 |
| mood |
1 |
mcns |
1 |
|
|
|
|
|
|
stroke |
7 |
| above |
1 |
levels |
1 |
|
|
|
|
|
|
worldwide |
7 |
| regeneration |
1 |
women |
1 |
|
|
|
|
|
|
required |
7 |
| cytokine |
1 |
costs |
1 |
|
|
|
|
|
|
essential |
7 |
| rate |
1 |
surgery |
1 |
|
|
|
|
|
|
damage |
7 |
| latitude |
1 |
mdd |
1 |
|
|
|
|
|
|
myocardial |
7 |
| feature |
1 |
or |
1 |
|
|
|
|
|
|
injury |
7 |
| 001 |
1 |
nucleotides |
1 |
|
|
|
|
|
|
sequences |
7 |
| while |
1 |
midac |
1 |
|
|
|
|
|
|
temperature |
7 |
| uncinate |
1 |
can |
1 |
|
|
|
|
|
|
14 |
7 |
| variability |
1 |
macaques |
1 |
|
|
|
|
|
|
disorder |
7 |
| ps |
1 |
today |
1 |
|
|
|
|
|
|
soil |
7 |
| center |
1 |
expression |
1 |
|
|
|
|
|
|
cycle |
7 |
| alpha |
1 |
stemi |
1 |
|
|
|
|
|
|
small |
7 |
| network |
1 |
s4 |
1 |
|
|
|
|
|
|
addition |
7 |
| versus |
1 |
interrelationships |
1 |
|
|
|
|
|
|
support |
7 |
| plant |
1 |
ancestry |
1 |
|
|
|
|
|
|
evolution |
7 |
| 2500 |
1 |
grh |
1 |
|
|
|
|
|
|
plants |
7 |
| shifts |
1 |
ingestion |
1 |
|
|
|
|
|
|
processing |
7 |
| structure |
1 |
progenitors |
1 |
|
|
|
|
|
|
beta |
7 |
| transcallosal |
1 |
nmdars |
1 |
|
|
|
|
|
|
delivery |
7 |
| gender |
1 |
nutrition |
1 |
|
|
|
|
|
|
2019 |
7 |
| genomic |
1 |
anticoagulants |
1 |
|
|
|
|
|
|
membrane |
7 |
| sinonasal |
1 |
seq |
1 |
|
|
|
|
|
|
degradation |
7 |
| increased |
1 |
processing |
1 |
|
|
|
|
|
|
ce |
7 |
| ancestral |
1 |
with |
1 |
|
|
|
|
|
|
material |
7 |
| neutrophil |
1 |
fragments |
1 |
|
|
|
|
|
|
numerous |
7 |
| embryonic |
1 |
alveologenesis |
1 |
|
|
|
|
|
|
host |
7 |
| predictive |
1 |
gvhd |
1 |
|
|
|
|
|
|
issue |
7 |
| preterm |
1 |
egfr |
1 |
|
|
|
|
|
|
early |
7 |
| rise |
1 |
locations |
1 |
|
|
|
|
|
|
efficacy |
7 |
| facilitate |
1 |
icl |
1 |
|
|
|
|
|
|
environmental |
7 |
| action |
1 |
annotation |
1 |
|
|
|
|
|
|
experimental |
7 |
| thread |
1 |
metastasis |
1 |
|
|
|
|
|
|
blood |
7 |
| myeloid |
1 |
fasciculus |
1 |
|
|
|
|
|
|
signals |
7 |
| growth |
1 |
energy |
1 |
|
|
|
|
|
|
open |
7 |
| origin |
1 |
azithromycin |
1 |
|
|
|
|
|
|
symptoms |
7 |
| adult |
1 |
synuclein |
1 |
|
|
|
|
|
|
chronic |
7 |
| success |
1 |
cc |
1 |
|
|
|
|
|
|
sex |
7 |
| resection |
1 |
sensors |
1 |
|
|
|
|
|
|
nm |
7 |
| populations |
1 |
emw |
1 |
|
|
|
|
|
|
intervention |
7 |
| aggregated |
1 |
difference |
1 |
|
|
|
|
|
|
strategies |
7 |
| gc |
1 |
12 |
1 |
|
|
|
|
|
|
advances |
7 |
| hip |
1 |
connectivity |
1 |
|
|
|
|
|
|
cardiac |
7 |
| repeat |
1 |
findings |
1 |
|
|
|
|
|
|
independent |
7 |
| hyperpolarization |
1 |
elucidation |
1 |
|
|
|
|
|
|
recently |
7 |
| are |
1 |
disparities |
1 |
|
|
|
|
|
|
white |
7 |
| concentrations |
1 |
trials |
1 |
|
|
|
|
|
|
what |
7 |
| culture |
1 |
gap |
1 |
|
|
|
|
|
|
animal |
7 |
| cd19 |
1 |
instability |
1 |
|
|
|
|
|
|
benefit |
7 |
| change |
1 |
microbiome |
1 |
|
|
|
|
|
|
ph |
7 |
| pigs |
1 |
frailty |
1 |
|
|
|
|
|
|
local |
6 |
| paddy |
1 |
lvs |
1 |
|
|
|
|
|
|
environment |
6 |
| phosphorylate |
1 |
lineage |
1 |
|
|
|
|
|
|
bacteria |
6 |
| key |
1 |
performance |
1 |
|
|
|
|
|
|
enigmatic |
6 |
| infection |
1 |
excitation |
1 |
|
|
|
|
|
|
motor |
6 |
| uncommon |
1 |
birth |
1 |
|
|
|
|
|
|
self |
6 |
| microbiota |
1 |
divergence |
1 |
|
|
|
|
|
|
bound |
6 |
| have |
1 |
leukaemia |
1 |
|
|
|
|
|
|
developmental |
6 |
| native |
1 |
temperature |
1 |
|
|
|
|
|
|
achieved |
6 |
| climate |
1 |
deficit |
1 |
|
|
|
|
|
|
histone |
6 |
| tumorigenesis |
1 |
infections |
1 |
|
|
|
|
|
|
linked |
6 |
| gene |
1 |
conclusions |
1 |
|
|
|
|
|
|
inflammatory |
6 |
| experiences |
1 |
contaminants |
1 |
|
|
|
|
|
|
suggesting |
6 |
| identified |
1 |
malaria |
1 |
|
|
|
|
|
|
molecules |
6 |
| 19 |
1 |
velocity |
1 |
|
|
|
|
|
|
reactions |
6 |
| combination |
1 |
pathogens |
1 |
|
|
|
|
|
|
regional |
6 |
| released |
1 |
fractures |
1 |
|
|
|
|
|
|
world |
6 |
| object |
1 |
nesting |
1 |
|
|
|
|
|
|
widely |
6 |
| mnds |
1 |
expansions |
1 |
|
|
|
|
|
|
transplantation |
6 |
| antigens |
1 |
lofg |
1 |
|
|
|
|
|
|
ad |
6 |
| clean |
1 |
specified |
1 |
|
|
|
|
|
|
sequencing |
6 |
| saturation |
1 |
improvement |
1 |
|
|
|
|
|
|
wnt |
6 |
| experiments |
1 |
typically |
1 |
|
|
|
|
|
|
period |
6 |
| parasites |
1 |
contamination |
1 |
|
|
|
|
|
|
influence |
6 |
| some |
1 |
blbc |
1 |
|
|
|
|
|
|
often |
6 |
| primary |
1 |
22 |
1 |
|
|
|
|
|
|
acquired |
6 |
| subglacial |
1 |
soils |
1 |
|
|
|
|
|
|
men |
6 |
| million |
1 |
replication |
1 |
|
|
|
|
|
|
increase |
6 |
| maize |
1 |
gsk3beta |
1 |
|
|
|
|
|
|
indicating |
6 |
| osteoarthritic |
1 |
pwh |
1 |
|
|
|
|
|
|
any |
6 |
| expression |
1 |
hl |
1 |
|
|
|
|
|
|
causal |
6 |
| optimised |
1 |
generally |
1 |
|
|
|
|
|
|
extensively |
6 |
| nrr |
1 |
myocardium |
1 |
|
|
|
|
|
|
behind |
6 |
| polygenic |
1 |
forcing |
1 |
|
|
|
|
|
|
progress |
6 |
| y |
1 |
minerals |
1 |
|
|
|
|
|
|
fundamental |
6 |
| nmj |
1 |
network |
1 |
|
|
|
|
|
|
radiation |
6 |
| lymphoma |
1 |
studies |
1 |
|
|
|
|
|
|
dose |
6 |
| oer |
1 |
heads |
1 |
|
|
|
|
|
|
highly |
6 |
| molecules |
1 |
hai |
1 |
|
|
|
|
|
|
people |
6 |
| chain |
1 |
concentration |
1 |
|
|
|
|
|
|
materials |
6 |
| gvhd |
1 |
nta |
1 |
|
|
|
|
|
|
united |
6 |
| lymphocytic |
1 |
relapse |
1 |
|
|
|
|
|
|
burden |
6 |
| provider |
1 |
resolve |
1 |
|
|
|
|
|
|
approaches |
6 |
| gestational |
1 |
feps |
1 |
|
|
|
|
|
|
find |
6 |
| life |
1 |
pilots |
1 |
|
|
|
|
|
|
strongly |
6 |
| breast |
1 |
endpoint |
1 |
|
|
|
|
|
|
visual |
6 |
| patients |
1 |
meltwaters |
1 |
|
|
|
|
|
|
25 |
6 |
| biosynthetic |
1 |
observation |
1 |
|
|
|
|
|
|
phenotypes |
6 |
| organization |
1 |
years |
1 |
|
|
|
|
|
|
repair |
6 |
| tend |
1 |
sle |
1 |
|
|
|
|
|
|
morbidity |
6 |
| subsequently |
1 |
test |
1 |
|
|
|
|
|
|
accurately |
6 |
| progress |
1 |
protocol |
1 |
|
|
|
|
|
|
identify |
6 |
| pi |
1 |
catalysis |
1 |
|
|
|
|
|
|
decades |
6 |
| symmetric |
1 |
salience |
1 |
|
|
|
|
|
|
ecological |
6 |
| amyloid |
1 |
then |
1 |
|
|
|
|
|
|
contribution |
6 |
| neurodegenerative |
1 |
role |
1 |
|
|
|
|
|
|
undefined |
6 |
| transplants |
1 |
adaptations |
1 |
|
|
|
|
|
|
e |
6 |
| among |
1 |
pestis |
1 |
|
|
|
|
|
|
kidney |
6 |
| nmr |
1 |
metamaterials |
1 |
|
|
|
|
|
|
endothelial |
6 |
| mci |
1 |
radiography |
1 |
|
|
|
|
|
|
application |
6 |
| synthesize |
1 |
fav |
1 |
|
|
|
|
|
|
groups |
6 |
| water |
1 |
electrocatalysts |
1 |
|
|
|
|
|
|
metal |
6 |
| pregnancy |
1 |
filopodia |
1 |
|
|
|
|
|
|
nutrient |
6 |
| different |
1 |
gels |
1 |
|
|
|
|
|
|
affects |
6 |
| use |
1 |
states |
1 |
|
|
|
|
|
|
scale |
6 |
| intracellular |
1 |
reinfection |
1 |
|
|
|
|
|
|
fluorescence |
6 |
| tropical |
1 |
bronchiolitis |
1 |
|
|
|
|
|
|
predicted |
6 |
| digit |
1 |
safety |
1 |
|
|
|
|
|
|
sensory |
6 |
| syntrophic |
1 |
membranes |
1 |
|
|
|
|
|
|
pattern |
6 |
| tuberculosis |
1 |
age |
1 |
|
|
|
|
|
|
regulating |
6 |
| few |
1 |
executed |
1 |
|
|
|
|
|
|
bulk |
6 |
| superimposable |
1 |
sp |
1 |
|
|
|
|
|
|
relevant |
6 |
| bone |
1 |
status |
1 |
|
|
|
|
|
|
cost |
6 |
| rates |
1 |
uptake |
1 |
|
|
|
|
|
|
focused |
6 |
| characterization |
1 |
walking |
1 |
|
|
|
|
|
|
tools |
6 |
| als |
1 |
models |
1 |
|
|
|
|
|
|
alpha |
6 |
| f |
1 |
pathology |
1 |
|
|
|
|
|
|
immunity |
6 |
| sp |
1 |
gut |
1 |
|
|
|
|
|
|
size |
6 |
| aortic |
1 |
diseases |
1 |
|
|
|
|
|
|
site |
6 |
| distribution |
1 |
vs |
1 |
|
|
|
|
|
|
associations |
6 |
| therapies |
1 |
application |
1 |
|
|
|
|
|
|
adjustment |
6 |
| induced |
1 |
recovery |
1 |
|
|
|
|
|
|
odds |
6 |
| converted |
1 |
pea |
1 |
|
|
|
|
|
|
replication |
6 |
| natural |
1 |
associations |
1 |
|
|
|
|
|
|
lead |
6 |
| baseline |
1 |
forest |
1 |
|
|
|
|
|
|
infections |
6 |
| scaffold |
1 |
morphology |
1 |
|
|
|
|
|
|
characteristics |
6 |
| question |
1 |
mirnas |
1 |
|
|
|
|
|
|
b |
6 |
| access |
1 |
relevance |
1 |
|
|
|
|
|
|
protective |
6 |
| antimicrobials |
1 |
loss |
1 |
|
|
|
|
|
|
developing |
6 |
| cisternal |
1 |
2019 |
1 |
|
|
|
|
|
|
network |
6 |
| bcg |
1 |
adhesion |
1 |
|
|
|
|
|
|
barrier |
6 |
| macroecological |
1 |
uncertainties |
1 |
|
|
|
|
|
|
regulate |
6 |
| being |
1 |
snps |
1 |
|
|
|
|
|
|
defects |
6 |
| routine |
1 |
taf |
1 |
|
|
|
|
|
|
controversial |
6 |
| not |
1 |
transfers |
1 |
|
|
|
|
|
|
until |
6 |
| evaporation |
1 |
indications |
1 |
|
|
|
|
|
|
work |
6 |
| level |
1 |
care |
1 |
|
|
|
|
|
|
bone |
6 |
| costs |
1 |
reinstatement |
1 |
|
|
|
|
|
|
d |
6 |
| hs |
1 |
history |
1 |
|
|
|
|
|
|
same |
6 |
| visual |
1 |
colonoscopy |
1 |
|
|
|
|
|
|
therapies |
6 |
| outline |
1 |
magmaris |
1 |
|
|
|
|
|
|
following |
6 |
| healing |
1 |
cores |
1 |
|
|
|
|
|
|
pre |
6 |
| parasite |
1 |
scales |
1 |
|
|
|
|
|
|
cd4 |
6 |
| encoded |
1 |
characteristics |
1 |
|
|
|
|
|
|
question |
6 |
| zikv |
1 |
white |
1 |
|
|
|
|
|
|
attention |
6 |
| bonding |
1 |
detection |
1 |
|
|
|
|
|
|
exposure |
6 |
| mechanisms |
1 |
complex |
1 |
|
|
|
|
|
|
initiation |
6 |
| 783 |
1 |
analysis |
1 |
|
|
|
|
|
|
enzymes |
6 |
| stress |
1 |
may |
1 |
|
|
|
|
|
|
action |
6 |
| congenita |
1 |
implementation |
1 |
|
|
|
|
|
|
facial |
6 |
| generated |
1 |
crp |
1 |
|
|
|
|
|
|
million |
6 |
| regenerate |
1 |
brain |
1 |
|
|
|
|
|
|
older |
6 |
| capillaries |
1 |
system |
1 |
|
|
|
|
|
|
contrast |
6 |
| tauopathy |
1 |
ursodiol |
1 |
|
|
|
|
|
|
selective |
6 |
| stakeholder |
1 |
01 |
1 |
|
|
|
|
|
|
channel |
5 |
| folding |
1 |
interact |
1 |
|
|
|
|
|
|
via |
5 |
| switch |
1 |
perspectives |
1 |
|
|
|
|
|
|
nevertheless |
5 |
| strategies |
1 |
906 |
1 |
|
|
|
|
|
|
regulated |
5 |
| physical |
1 |
partnership |
1 |
|
|
|
|
|
|
limits |
5 |
| modulation |
1 |
lags |
1 |
|
|
|
|
|
|
capacity |
5 |
| zeolite |
1 |
preferences |
1 |
|
|
|
|
|
|
times |
5 |
| infrastructure |
1 |
mpr |
1 |
|
|
|
|
|
|
vs |
5 |
| traveling |
1 |
mbf |
1 |
|
|
|
|
|
|
01 |
5 |
| i |
1 |
angiogenesis |
1 |
|
|
|
|
|
|
link |
5 |
| thromboembolism |
1 |
cilia |
1 |
|
|
|
|
|
|
conserved |
5 |
| exercise |
1 |
rhabdoms |
1 |
|
|
|
|
|
|
combination |
5 |
| markers |
1 |
solution |
1 |
|
|
|
|
|
|
practice |
5 |
| trpc |
1 |
group |
1 |
|
|
|
|
|
|
followed |
5 |
| pathogen |
1 |
sex |
1 |
|
|
|
|
|
|
plays |
5 |
| freshwater |
1 |
arrest |
1 |
|
|
|
|
|
|
pain |
5 |
| older |
1 |
lipids |
1 |
|
|
|
|
|
|
numbers |
5 |
| achieved |
1 |
cough |
1 |
|
|
|
|
|
|
lysine |
5 |
| microbiome |
1 |
modulation |
1 |
|
|
|
|
|
|
trials |
5 |
| 2d |
1 |
n |
1 |
|
|
|
|
|
|
variable |
5 |
| formed |
1 |
support |
1 |
|
|
|
|
|
|
severity |
5 |
| applications |
1 |
waves |
1 |
|
|
|
|
|
|
targeted |
5 |
| systemic |
1 |
vte |
1 |
|
|
|
|
|
|
contributes |
5 |
| if |
1 |
intensity |
1 |
|
|
|
|
|
|
receptor |
5 |
| et |
1 |
channels |
1 |
|
|
|
|
|
|
result |
5 |
| undamped |
1 |
heterogeneity |
1 |
|
|
|
|
|
|
fold |
5 |
| sequencing |
1 |
genomes |
1 |
|
|
|
|
|
|
second |
5 |
| reward |
1 |
micrographs |
1 |
|
|
|
|
|
|
gaps |
5 |
| females |
1 |
machinery |
1 |
|
|
|
|
|
|
aging |
5 |
| general |
1 |
aob |
1 |
|
|
|
|
|
|
selection |
5 |
| vf |
1 |
epithelium |
1 |
|
|
|
|
|
|
five |
5 |
| eye |
1 |
discuss |
1 |
|
|
|
|
|
|
remain |
5 |
| hierarchical |
1 |
agent |
1 |
|
|
|
|
|
|
malignant |
5 |
| domains |
1 |
any |
1 |
|
|
|
|
|
|
variants |
5 |
| public |
1 |
stiffness |
1 |
|
|
|
|
|
|
rise |
5 |
| 4 |
1 |
samples |
1 |
|
|
|
|
|
|
interest |
5 |
| barrier |
1 |
techniques |
1 |
|
|
|
|
|
|
aspects |
5 |
| ligase |
1 |
hrqol |
1 |
|
|
|
|
|
|
networks |
5 |
| estuarine |
1 |
mges |
1 |
|
|
|
|
|
|
status |
5 |
| model |
1 |
attention |
1 |
|
|
|
|
|
|
standard |
5 |
| serine |
1 |
groundwaters |
1 |
|
|
|
|
|
|
reported |
5 |
| microcolonies |
1 |
objects |
1 |
|
|
|
|
|
|
heterogeneous |
5 |
| cold |
1 |
bbb |
1 |
|
|
|
|
|
|
preventing |
5 |
| time |
1 |
recruiters |
1 |
|
|
|
|
|
|
kinase |
5 |
| interactions |
1 |
wetlands |
1 |
|
|
|
|
|
|
g |
5 |
| cns |
1 |
synapse |
1 |
|
|
|
|
|
|
disorders |
5 |
| mal |
1 |
availability |
1 |
|
|
|
|
|
|
occurred |
5 |
| zipper |
1 |
ocd |
1 |
|
|
|
|
|
|
sleep |
5 |
| appropriate |
1 |
symptoms |
1 |
|
|
|
|
|
|
sars |
5 |
| diminished |
1 |
inflammation |
1 |
|
|
|
|
|
|
cov |
5 |
| questions |
1 |
telomeres |
1 |
|
|
|
|
|
|
public |
5 |
| antigen |
1 |
simultaneously |
1 |
|
|
|
|
|
|
show |
5 |
| confounding |
1 |
gas |
1 |
|
|
|
|
|
|
increases |
5 |
| protease |
1 |
consuming |
1 |
|
|
|
|
|
|
median |
5 |
| correction |
1 |
hypothesis |
1 |
|
|
|
|
|
|
29 |
5 |
| tools |
1 |
involvement |
1 |
|
|
|
|
|
|
field |
5 |
| neurons |
1 |
solid |
1 |
|
|
|
|
|
|
driving |
5 |
| internal |
1 |
motif |
1 |
|
|
|
|
|
|
surfaces |
5 |
| particles |
1 |
management |
1 |
|
|
|
|
|
|
background |
5 |
| morphology |
1 |
its |
1 |
|
|
|
|
|
|
driver |
5 |
| orai3 |
1 |
complexes |
1 |
|
|
|
|
|
|
clusters |
5 |
| synapses |
1 |
algorithms |
1 |
|
|
|
|
|
|
animals |
5 |
| relapse |
1 |
methylome |
1 |
|
|
|
|
|
|
optimal |
5 |
| unmasking |
1 |
equity |
1 |
|
|
|
|
|
|
phenotypic |
5 |
| outcomes |
1 |
assemble |
1 |
|
|
|
|
|
|
debated |
5 |
| side |
1 |
18 |
1 |
|
|
|
|
|
|
investigated |
5 |
| studies |
1 |
speed |
1 |
|
|
|
|
|
|
separation |
5 |
| charge |
1 |
transfer |
1 |
|
|
|
|
|
|
side |
5 |
|
|
|
|
|
|
|
|
|
|
modulates |
5 |
|
|
|
|
|
|
|
|
|
|
homeostasis |
5 |
|
|
|
|
|
|
|
|
|
|
sources |
5 |
|
|
|
|
|
|
|
|
|
|
marine |
5 |
|
|
|
|
|
|
|
|
|
|
terrestrial |
5 |
|
|
|
|
|
|
|
|
|
|
ii |
5 |
|
|
|
|
|
|
|
|
|
|
imaging |
5 |
|
|
|
|
|
|
|
|
|
|
temporal |
5 |
|
|
|
|
|
|
|
|
|
|
either |
5 |
|
|
|
|
|
|
|
|
|
|
ice |
5 |
|
|
|
|
|
|
|
|
|
|
thought |
5 |
|
|
|
|
|
|
|
|
|
|
unresolved |
5 |
|
|
|
|
|
|
|
|
|
|
fine |
5 |
|
|
|
|
|
|
|
|
|
|
require |
5 |
|
|
|
|
|
|
|
|
|
|
centers |
5 |
|
|
|
|
|
|
|
|
|
|
phenotype |
5 |
|
|
|
|
|
|
|
|
|
|
heterogeneity |
5 |
|
|
|
|
|
|
|
|
|
|
less |
5 |
|
|
|
|
|
|
|
|
|
|
strong |
5 |
|
|
|
|
|
|
|
|
|
|
quality |
5 |
|
|
|
|
|
|
|
|
|
|
endogenous |
5 |
|
|
|
|
|
|
|
|
|
|
beyond |
5 |
|
|
|
|
|
|
|
|
|
|
case |
5 |
|
|
|
|
|
|
|
|
|
|
contribute |
5 |
|
|
|
|
|
|
|
|
|
|
modulation |
5 |
|
|
|
|
|
|
|
|
|
|
expansion |
5 |
|
|
|
|
|
|
|
|
|
|
proliferation |
5 |
|
|
|
|
|
|
|
|
|
|
little |
5 |
|
|
|
|
|
|
|
|
|
|
success |
5 |
|
|
|
|
|
|
|
|
|
|
globally |
5 |
|
|
|
|
|
|
|
|
|
|
organic |
5 |
|
|
|
|
|
|
|
|
|
|
previous |
5 |
|
|
|
|
|
|
|
|
|
|
rnas |
5 |
|
|
|
|
|
|
|
|
|
|
transition |
5 |
|
|
|
|
|
|
|
|
|
|
children |
5 |
|
|
|
|
|
|
|
|
|
|
demonstrated |
5 |
|
|
|
|
|
|
|
|
|
|
coordinate |
5 |
|
|
|
|
|
|
|
|
|
|
step |
5 |
|
|
|
|
|
|
|
|
|
|
cues |
5 |
|
|
|
|
|
|
|
|
|
|
test |
5 |
|
|
|
|
|
|
|
|
|
|
did |
5 |
|
|
|
|
|
|
|
|
|
|
genomic |
5 |
|
|
|
|
|
|
|
|
|
|
chain |
5 |
|
|
|
|
|
|
|
|
|
|
regions |
5 |
|
|
|
|
|
|
|
|
|
|
trait |
5 |
|
|
|
|
|
|
|
|
|
|
22 |
5 |
|
|
|
|
|
|
|
|
|
|
nitrogen |
5 |
|
|
|
|
|
|
|
|
|
|
distinct |
5 |
|
|
|
|
|
|
|
|
|
|
extinction |
5 |
|
|
|
|
|
|
|
|
|
|
neuronal |
5 |
|
|
|
|
|
|
|
|
|
|
lineage |
5 |
|
|
|
|
|
|
|
|
|
|
contact |
5 |
|
|
|
|
|
|
|
|
|
|
days |
5 |
|
|
|
|
|
|
|
|
|
|
performance |
5 |
|
|
|
|
|
|
|
|
|
|
20 |
5 |
|
|
|
|
|
|
|
|
|
|
prognosis |
5 |
|
|
|
|
|
|
|
|
|
|
relapse |
5 |
|
|
|
|
|
|
|
|
|
|
graft |
5 |
|
|
|
|
|
|
|
|
|
|
reaction |
5 |
|
|
|
|
|
|
|
|
|
|
contributions |
5 |
|
|
|
|
|
|
|
|
|
|
dysfunction |
5 |
|
|
|
|
|
|
|
|
|
|
ambiguous |
5 |
|
|
|
|
|
|
|
|
|
|
peripheral |
5 |
|
|
|
|
|
|
|
|
|
|
coordinated |
5 |
|
|
|
|
|
|
|
|
|
|
surgery |
5 |
|
|
|
|
|
|
|
|
|
|
encoded |
5 |
|
|
|
|
|
|
|
|
|
|
adjusted |
5 |
|
|
|
|
|
|
|
|
|
|
ct |
5 |
|
|
|
|
|
|
|
|
|
|
anti |
5 |
|
|
|
|
|
|
|
|
|
|
antibody |
5 |
|
|
|
|
|
|
|
|
|
|
native |
5 |
|
|
|
|
|
|
|
|
|
|
80 |
5 |
|
|
|
|
|
|
|
|
|
|
circuit |
5 |
|
|
|
|
|
|
|
|
|
|
relationships |
5 |
|
|
|
|
|
|
|
|
|
|
power |
5 |
|
|
|
|
|
|
|
|
|
|
identifying |
5 |
|
|
|
|
|
|
|
|
|
|
elevated |
5 |
|
|
|
|
|
|
|
|
|
|
characterization |
5 |
|
|
|
|
|
|
|
|
|
|
potentially |
5 |
|
|
|
|
|
|
|
|
|
|
inflammation |
5 |
|
|
|
|
|
|
|
|
|
|
each |
5 |
|
|
|
|
|
|
|
|
|
|
wide |
5 |
|
|
|
|
|
|
|
|
|
|
distribution |
5 |
|
|
|
|
|
|
|
|
|
|
correction |
5 |
|
|
|
|
|
|
|
|
|
|
promote |
5 |
|
|
|
|
|
|
|
|
|
|
existing |
5 |
|
|
|
|
|
|
|
|
|
|
mass |
5 |
|
|
|
|
|
|
|
|
|
|
near |
5 |
|
|
|
|
|
|
|
|
|
|
mammalian |
5 |
|
|
|
|
|
|
|
|
|
|
direct |
5 |
|
|
|
|
|
|
|
|
|
|
molecule |
5 |
|
|
|
|
|
|
|
|
|
|
crucial |
5 |
|
|
|
|
|
|
|
|
|
|
type |
5 |
|
|
|
|
|
|
|
|
|
|
complete |
5 |
|
|
|
|
|
|
|
|
|
|
stem |
5 |
|
|
|
|
|
|
|
|
|
|
gap |
4 |
|
|
|
|
|
|
|
|
|
|
matter |
4 |
|
|
|
|
|
|
|
|
|
|
synaptic |
4 |
|
|
|
|
|
|
|
|
|
|
fate |
4 |
|
|
|
|
|
|
|
|
|
|
positive |
4 |
|
|
|
|
|
|
|
|
|
|
electron |
4 |
|
|
|
|
|
|
|
|
|
|
predicting |
4 |
|
|
|
|
|
|
|
|
|
|
loci |
4 |
|
|
|
|
|
|
|
|
|
|
sensitive |
4 |
|
|
|
|
|
|
|
|
|
|
appropriate |
4 |
|
|
|
|
|
|
|
|
|
|
inputs |
4 |
|
|
|
|
|
|
|
|
|
|
acid |
4 |
|
|
|
|
|
|
|
|
|
|
sensing |
4 |
|
|
|
|
|
|
|
|
|
|
27 |
4 |
|
|
|
|
|
|
|
|
|
|
akt |
4 |
|
|
|
|
|
|
|
|
|
|
inhibitors |
4 |
|
|
|
|
|
|
|
|
|
|
driven |
4 |
|
|
|
|
|
|
|
|
|
|
computational |
4 |
|
|
|
|
|
|
|
|
|
|
er |
4 |
|
|
|
|
|
|
|
|
|
|
example |
4 |
|
|
|
|
|
|
|
|
|
|
variations |
4 |
|
|
|
|
|
|
|
|
|
|
included |
4 |
|
|
|
|
|
|
|
|
|
|
given |
4 |
|
|
|
|
|
|
|
|
|
|
pathophysiology |
4 |
|
|
|
|
|
|
|
|
|
|
access |
4 |
|
|
|
|
|
|
|
|
|
|
coverage |
4 |
|
|
|
|
|
|
|
|
|
|
platelet |
4 |
|
|
|
|
|
|
|
|
|
|
before |
4 |
|
|
|
|
|
|
|
|
|
|
daa |
4 |
|
|
|
|
|
|
|
|
|
|
main |
4 |
|
|
|
|
|
|
|
|
|
|
100 |
4 |
|
|
|
|
|
|
|
|
|
|
third |
4 |
|
|
|
|
|
|
|
|
|
|
female |
4 |
|
|
|
|
|
|
|
|
|
|
prostate |
4 |
|
|
|
|
|
|
|
|
|
|
around |
4 |
|
|
|
|
|
|
|
|
|
|
interact |
4 |
|
|
|
|
|
|
|
|
|
|
transformation |
4 |
|
|
|
|
|
|
|
|
|
|
areas |
4 |
|
|
|
|
|
|
|
|
|
|
larger |
4 |
|
|
|
|
|
|
|
|
|
|
post |
4 |
|
|
|
|
|
|
|
|
|
|
prior |
4 |
|
|
|
|
|
|
|
|
|
|
then |
4 |
|
|
|
|
|
|
|
|
|
|
sequence |
4 |
|
|
|
|
|
|
|
|
|
|
treg |
4 |
|
|
|
|
|
|
|
|
|
|
60 |
4 |
|
|
|
|
|
|
|
|
|
|
chemotherapy |
4 |
|
|
|
|
|
|
|
|
|
|
frequently |
4 |
|
|
|
|
|
|
|
|
|
|
layer |
4 |
|
|
|
|
|
|
|
|
|
|
transduction |
4 |
|
|
|
|
|
|
|
|
|
|
considered |
4 |
|
|
|
|
|
|
|
|
|
|
described |
4 |
|
|
|
|
|
|
|
|
|
|
needed |
4 |
|
|
|
|
|
|
|
|
|
|
adults |
4 |
|
|
|
|
|
|
|
|
|
|
ca |
4 |
|
|
|
|
|
|
|
|
|
|
intense |
4 |
|
|
|
|
|
|
|
|
|
|
altered |
4 |
|
|
|
|
|
|
|
|
|
|
remains |
4 |
|
|
|
|
|
|
|
|
|
|
least |
4 |
|
|
|
|
|
|
|
|
|
|
200 |
4 |
|
|
|
|
|
|
|
|
|
|
colon |
4 |
|
|
|
|
|
|
|
|
|
|
family |
4 |
|
|
|
|
|
|
|
|
|
|
compounds |
4 |
|
|
|
|
|
|
|
|
|
|
intake |
4 |
|
|
|
|
|
|
|
|
|
|
transplant |
4 |
|
|
|
|
|
|
|
|
|
|
rejection |
4 |
|
|
|
|
|
|
|
|
|
|
addressed |
4 |
|
|
|
|
|
|
|
|
|
|
tumors |
4 |
|
|
|
|
|
|
|
|
|
|
play |
4 |
|
|
|
|
|
|
|
|
|
|
phase |
4 |
|
|
|
|
|
|
|
|
|
|
robust |
4 |
|
|
|
|
|
|
|
|
|
|
organ |
4 |
|
|
|
|
|
|
|
|
|
|
microbial |
4 |
|
|
|
|
|
|
|
|
|
|
communities |
4 |
|
|
|
|
|
|
|
|
|
|
untested |
4 |
|
|
|
|
|
|
|
|
|
|
exact |
4 |
|
|
|
|
|
|
|
|
|
|
unique |
4 |
|
|
|
|
|
|
|
|
|
|
regulates |
4 |
|
|
|
|
|
|
|
|
|
|
intensive |
4 |
|
|
|
|
|
|
|
|
|
|
diagnostic |
4 |
|
|
|
|
|
|
|
|
|
|
social |
4 |
|
|
|
|
|
|
|
|
|
|
drivers |
4 |
|
|
|
|
|
|
|
|
|
|
transcription |
4 |
|
|
|
|
|
|
|
|
|
|
shape |
4 |
|
|
|
|
|
|
|
|
|
|
act |
4 |
|
|
|
|
|
|
|
|
|
|
alter |
4 |
|
|
|
|
|
|
|
|
|
|
proteome |
4 |
|
|
|
|
|
|
|
|
|
|
solid |
4 |
|
|
|
|
|
|
|
|
|
|
coordination |
4 |
|
|
|
|
|
|
|
|
|
|
substrate |
4 |
|
|
|
|
|
|
|
|
|
|
asthma |
4 |
|
|
|
|
|
|
|
|
|
|
unexplained |
4 |
|
|
|
|
|
|
|
|
|
|
score |
4 |
|
|
|
|
|
|
|
|
|
|
affected |
4 |
|
|
|
|
|
|
|
|
|
|
26 |
4 |
|
|
|
|
|
|
|
|
|
|
respectively |
4 |
|
|
|
|
|
|
|
|
|
|
intracellular |
4 |
|
|
|
|
|
|
|
|
|
|
complexes |
4 |
|
|
|
|
|
|
|
|
|
|
able |
4 |
|
|
|
|
|
|
|
|
|
|
uncharacterized |
4 |
|
|
|
|
|
|
|
|
|
|
drive |
4 |
|
|
|
|
|
|
|
|
|
|
effectiveness |
4 |
|
|
|
|
|
|
|
|
|
|
first |
4 |
|
|
|
|
|
|
|
|
|
|
ion |
4 |
|
|
|
|
|
|
|
|
|
|
alpha2 |
4 |
|
|
|
|
|
|
|
|
|
|
cortical |
4 |
|
|
|
|
|
|
|
|
|
|
supporting |
4 |
|
|
|
|
|
|
|
|
|
|
complications |
4 |
|
|
|
|
|
|
|
|
|
|
redox |
4 |
|
|
|
|
|
|
|
|
|
|
downstream |
4 |
|
|
|
|
|
|
|
|
|
|
implicated |
4 |
|
|
|
|
|
|
|
|
|
|
tropical |
4 |
|
|
|
|
|
|
|
|
|
|
variability |
4 |
|
|
|
|
|
|
|
|
|
|
phenomena |
4 |
|
|
|
|
|
|
|
|
|
|
incidence |
4 |
|
|
|
|
|
|
|
|
|
|
outcome |
4 |
|
|
|
|
|
|
|
|
|
|
pressure |
4 |
|
|
|
|
|
|
|
|
|
|
understudied |
4 |
|
|
|
|
|
|
|
|
|
|
polarity |
4 |
|
|
|
|
|
|
|
|
|
|
half |
4 |
|
|
|
|
|
|
|
|
|
|
adjusting |
4 |
|
|
|
|
|
|
|
|
|
|
six |
4 |
|
|
|
|
|
|
|
|
|
|
adp |
4 |
|
|
|
|
|
|
|
|
|
|
allows |
4 |
|
|
|
|
|
|
|
|
|
|
becomes |
4 |
|
|
|
|
|
|
|
|
|
|
terminal |
4 |
|
|
|
|
|
|
|
|
|
|
substrates |
4 |
|
|
|
|
|
|
|
|
|
|
catalytic |
4 |
|
|
|
|
|
|
|
|
|
|
zone |
4 |
|
|
|
|
|
|
|
|
|
|
cns |
4 |
|
|
|
|
|
|
|
|
|
|
ecosystem |
4 |
|
|
|
|
|
|
|
|
|
|
availability |
4 |
|
|
|
|
|
|
|
|
|
|
resources |
4 |
|
|
|
|
|
|
|
|
|
|
unsolved |
4 |
|
|
|
|
|
|
|
|
|
|
dengue |
4 |
|
|
|
|
|
|
|
|
|
|
ranging |
4 |
|
|
|
|
|
|
|
|
|
|
h |
4 |
|
|
|
|
|
|
|
|
|
|
persistent |
4 |
|
|
|
|
|
|
|
|
|
|
50 |
4 |
|
|
|
|
|
|
|
|
|
|
charge |
4 |
|
|
|
|
|
|
|
|
|
|
accuracy |
4 |
|
|
|
|
|
|
|
|
|
|
enable |
4 |
|
|
|
|
|
|
|
|
|
|
map |
4 |
|
|
|
|
|
|
|
|
|
|
proportion |
4 |
|
|
|
|
|
|
|
|
|
|
develop |
4 |
|
|
|
|
|
|
|
|
|
|
fraction |
4 |
|
|
|
|
|
|
|
|
|
|
hazard |
4 |
|
|
|
|
|
|
|
|
|
|
15 |
4 |
|
|
|
|
|
|
|
|
|
|
diabetes |
4 |
|
|
|
|
|
|
|
|
|
|
increasing |
4 |
|
|
|
|
|
|
|
|
|
|
diagnosis |
4 |
|
|
|
|
|
|
|
|
|
|
inter |
4 |
|
|
|
|
|
|
|
|
|
|
provided |
4 |
|
|
|
|
|
|
|
|
|
|
atmosphere |
4 |
|
|
|
|
|
|
|
|
|
|
identification |
4 |
|
|
|
|
|
|
|
|
|
|
today |
4 |
|
|
|
|
|
|
|
|
|
|
transcripts |
4 |
|
|
|
|
|
|
|
|
|
|
stabilization |
4 |
|
|
|
|
|
|
|
|
|
|
glutamate |
4 |
|
|
|
|
|
|
|
|
|
|
transporter |
4 |
|
|
|
|
|
|
|
|
|
|
plasticity |
4 |
|
|
|
|
|
|
|
|
|
|
variety |
4 |
|
|
|
|
|
|
|
|
|
|
tim |
4 |
|
|
|
|
|
|
|
|
|
|
represent |
4 |
|
|
|
|
|
|
|
|
|
|
shown |
4 |
|
|
|
|
|
|
|
|
|
|
biomarkers |
4 |
|
|
|
|
|
|
|
|
|
|
discovered |
4 |
|
|
|
|
|
|
|
|
|
|
much |
4 |
|
|
|
|
|
|
|
|
|
|
domains |
4 |
|
|
|
|
|
|
|
|
|
|
body |
4 |
|
|
|
|
|
|
|
|
|
|
recognized |
4 |
|
|
|
|
|
|
|
|
|
|
alternative |
4 |
|
|
|
|
|
|
|
|
|
|
lifespan |
4 |
|
|
|
|
|
|
|
|
|
|
memory |
4 |
|
|
|
|
|
|
|
|
|
|
susceptibility |
4 |
|
|
|
|
|
|
|
|
|
|
widespread |
4 |
|
|
|
|
|
|
|
|
|
|
techniques |
4 |
|
|
|
|
|
|
|
|
|
|
technical |
4 |
|
|
|
|
|
|
|
|
|
|
pathogenesis |
4 |
|
|
|
|
|
|
|
|
|
|
mechanical |
4 |
|
|
|
|
|
|
|
|
|
|
confidence |
4 |
|
|
|
|
|
|
|
|
|
|
interval |
4 |
|
|
|
|
|
|
|
|
|
|
gas |
4 |
|
|
|
|
|
|
|
|
|
|
cp |
4 |
|
|
|
|
|
|
|
|
|
|
bacterial |
4 |
|
|
|
|
|
|
|
|
|
|
community |
4 |
|
|
|
|
|
|
|
|
|
|
possible |
4 |
|
|
|
|
|
|
|
|
|
|
biosynthesis |
4 |
|
|
|
|
|
|
|
|
|
|
migration |
4 |
|
|
|
|
|
|
|
|
|
|
error |
4 |
|
|
|
|
|
|
|
|
|
|
splicing |
4 |
|
|
|
|
|
|
|
|
|
|
minimal |
4 |
|
|
|
|
|
|
|
|
|
|
length |
4 |
|
|
|
|
|
|
|
|
|
|
since |
4 |
|
|
|
|
|
|
|
|
|
|
independently |
4 |
|
|
|
|
|
|
|
|
|
|
transmission |
4 |
|
|
|
|
|
|
|
|
|
|
atomic |
4 |
|
|
|
|
|
|
|
|
|
|
cross |
4 |
|
|
|
|
|
|
|
|
|
|
demonstrate |
4 |
|
|
|
|
|
|
|
|
|
|
involves |
4 |
|
|
|
|
|
|
|
|
|
|
diameter |
4 |
|
|
|
|
|
|
|
|
|
|
infrared |
4 |
|
|
|
|
|
|
|
|
|
|
depression |
4 |
|
|
|
|
|
|
|
|
|
|
throughout |
4 |
|
|
|
|
|
|
|
|
|
|
nearly |
4 |
|
|
|
|
|
|
|
|
|
|
converted |
4 |
|
|
|
|
|
|
|
|
|
|
infarction |
4 |
|
|
|
|
|
|
|
|
|
|
cold |
4 |
|
|
|
|
|
|
|
|
|
|
suggests |
4 |
|
|
|
|
|
|
|
|
|
|
egfr |
4 |
|
|
|
|
|
|
|
|
|
|
array |
4 |
|
|
|
|
|
|
|
|
|
|
selectively |
4 |
|
|
|
|
|
|
|
|
|
|
samples |
4 |
|
|
|
|
|
|
|
|
|
|
benefits |
4 |
|
|
|
|
|
|
|
|
|
|
fractures |
4 |
|
|
|
|
|
|
|
|
|
|
pairs |
4 |
|
|
|
|
|
|
|
|
|
|
emerging |
4 |
|
|
|
|
|
|
|
|
|
|
rrms |
4 |
|
|
|
|
|
|
|
|
|
|
spms |
4 |
|
|
|
|
|
|
|
|
|
|
discriminatory |
4 |
|
|
|
|
|
|
|
|
|
|
mace |
4 |
|